Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Transcatheter mitral valve repair: a step back from the edge

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The invisible army of women in interventional cardiology: EAPCI Women mission to make them visible

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: Patients in a coma after cardiac arrest may have adversely affected drug absorption and metabolism. This study, the first of its kind, aimed to investigate the early pharmacokinetic and pharmacodynamic effects of ticagrelor administered through a nasogastric tube (NGT) to patients resuscitated after an out of hospital cardiac arrest (OHCA) and undergoing primary percutaneous coronary intervention (pPCI).

METHODS AND RESULTS: Blood samples were drawn at baseline and at two, four, six, eight, 12, and 24 hours and then daily for up to five days after administration of a 180 mg ticagrelor loading dose (LD), followed by 90 mg twice daily in 44 patients. The primary endpoint was the occurrence of high platelet reactivity (HPR) 12 hours after the LD. Assessment by VerifyNow (VFN) showed 96 (15.25-140.5) platelet reactivity units (PRU), and five (12%) patients exhibited HPR. Multiplate analysis showed 19 (12-29) units (U) at twelve hours, and three patients (7%) had HPR. Ticagrelor and its main metabolite AR-C124910XX concentrations were 85.2 (37.2-178.5) and 18.3 (6.4-52.4) ng/mL. Median times to sufficient platelet inhibition below the HPR limit were 3 (2-6) hours (VFN) and 4 (2-8) hours (Multiplate).

CONCLUSIONS: Ticagrelor, administered as crushed tablets through a nasogastric tube, leads to sufficient platelet inhibition after 12 hours, and in many cases earlier, in the vast majority of patients undergoing pPCI and subsequent intensive care management after an OHCA.

Original languageEnglish
JournalEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Volume12
Issue number14
Pages (from-to)1782-1788
Number of pages7
ISSN1774-024X
DOIs
Publication statusPublished - 20 Feb 2017

    Research areas

  • Adenosine, Blood Platelets, Female, Humans, Male, Middle Aged, Myocardial Infarction, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Platelet Function Tests, Purinergic P2Y Receptor Antagonists, Journal Article

ID: 52684111